RETROSENSE THERAPEUTICS, based in Ann Arbor, Michigan, is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). The RetroSense gene therapy technology has been demonstrated to confer light sensitivity to retinal nerve cells and restore functional vision in animal studies. The lead product candidate, RST-001, will be developed initially for RP with advanced dry-AMD as a follow-on indication.

In August 2016, RetroSense was purchased by Allergan Pharmaceuticals International, LTD and will continue to grow and develop its technology to restore vision.